FDA-approved Sexual & reproductive

Degarelix

Degarelix is a GnRH antagonist. It is filed in this library under sexual & reproductive, a navigation topic rather than a statement of where it acts. As a regulatory matter it has at least one product approved by the FDA.

Regulatory status

Degarelix has an FDA-approved product on the U.S. market, marketed as Firmagon under application NDA022201.

The current label is held by Ferring Pharmaceuticals Inc.

From the FDA label

What Degarelix is approved to treat

® is indicated for treatment of patients with advanced prostate cancer.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Degarelix, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on sexual & reproductive

Markers on this pathway

What is measured when the pituitary-gonadal axis is assessed

Degarelix's FDA-approved label indicates it for a condition managed by suppressing or controlling gonadotropin release. These are the markers clinicians use when assessing the pituitary-gonadal axis. They are listed here so you can read about them, not as a statement that Degarelix changes any of them.

Not sure what applies to you?

A 60-second questionnaire, reviewed by a U.S.-licensed physician.

Find my protocol

Educational reference only. This page explains what has been published about Degarelix. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides